Crossmark

Monitoring of argatroban and lepirudin anticoagulation in critically ill patients by conventional laboratory parameters and rotational thromboelastometry – a prospectively controlled randomized double-blind clinical trial

Crossref DOI link: https://doi.org/10.1186/s12871-018-0475-y

Published Online: 2018-02-09

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Beiderlinden, Martin

Werner, Patrick

Bahlmann, Astrid

Kemper, Johann

Brezina, Tobias

Schäfer, Maximilian

Görlinger, Klaus

Seidel, Holger

Kienbaum, Peter

Treschan, Tanja A. http://orcid.org/0000-0001-9363-1028
Funding

Funding for this research was provided by:

Mitsubishi Pharma
More Information

Article History

Received: 13 July 2017

Accepted: 18 January 2018

First Online: 9 February 2018

Ethics approval and consent to participate

: The Ethics committee of the Medical Faculty, Heinrich-Heine-University Düsseldorf, Germany and the Bundesinstitut für Arzneimittel, EudraCT number 2006–003122-28 approved this study (ExternalRef removednumber NCT00798525, registered 25th of November 2008). Written informed consent was obtained from patients or their legal guardian.

: Not applicable.

: Martin Beiderlinden: received honorary for lectures and financial support for research. All other authors declared no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Document is current

Any future updates will be listed below